| Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL F Vari, D Arpon, C Keane, MS Hertzberg, D Talaulikar, S Jain, Q Cui, ... Blood, The Journal of the American Society of Hematology 131 (16), 1809-1819, 2018 | 298 | 2018 |
| Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia JJ Castillo, RH Advani, AR Branagan, C Buske, MA Dimopoulos, S D'Sa, ... The Lancet Haematology 7 (11), e827-e837, 2020 | 123 | 2020 |
| Multiple myeloma: from diagnosis to treatment R Eslick, D Talaulikar Australian family physician 42 (10), 684-688, 2013 | 117 | 2013 |
| Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study JJ Castillo, G Itchaki, J Paludo, M Varettoni, C Buske, TA Eyre, JC Chavez, ... Blood, The Journal of the American Society of Hematology 133 (4), 299-305, 2019 | 89 | 2019 |
| Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study C Keane, F Vari, M Hertzberg, KA Lê Cao, MR Green, E Han, JF Seymour, ... The Lancet Haematology 2 (10), e445-e455, 2015 | 87 | 2015 |
| LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma C Keane, SC Law, C Gould, S Birch, MB Sabdia, L Merida de Long, ... Blood Advances 4 (7), 1367-1377, 2020 | 82 | 2020 |
| The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma C Keane, C Gould, K Jones, D Hamm, D Talaulikar, J Ellis, F Vari, S Birch, ... Clinical Cancer Research 23 (7), 1820-1828, 2017 | 78 | 2017 |
| Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial M Dimopoulos, RG Sanz, HP Lee, M Trneny, M Varettoni, S Opat, S D'Sa, ... Blood advances 4 (23), 6009-6018, 2020 | 69 | 2020 |
| The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma S Opat, A Tedeschi, K Linton, P McKay, B Hu, H Chan, J Jin, ... Clinical Cancer Research 27 (23), 6323-6332, 2021 | 64 | 2021 |
| Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients MR Wilson, TA Eyre, AA Kirkwood, N Wong Doo, C Soussain, S Choquet, ... Blood, The Journal of the American Society of Hematology 139 (16), 2499-2511, 2022 | 55 | 2022 |
| The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma C Keane, J Tobin, J Gunawardana, S Francis, G Gifford, S Gabrielli, A Gill, ... European journal of haematology 103 (3), 200-207, 2019 | 52 | 2019 |
| Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas D Talaulikar, A Choudhury, B Shadbolt, M Brown Leukemia & lymphoma 49 (5), 959-964, 2008 | 47 | 2008 |
| A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different … D Talaulikar, JX Gray, B Shadbolt, M McNiven, JE Dahlstrom Journal of clinical pathology 61 (1), 119-123, 2008 | 44 | 2008 |
| Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI) D Talaulikar, B Shadbolt, JE Dahlstrom, A McDonald Journal of hematology & oncology 2, 1-9, 2009 | 42 | 2009 |
| Health‐related quality of life in chronic coagulation disorders D Talaulikar, B Shadbolt, A McDonald, M Pidcock Haemophilia 12 (6), 633-642, 2006 | 40 | 2006 |
| Occult bone marrow involvement in patients with diffuse large B‐cell lymphoma: results of a pilot study D Talaulikar, JE Dahlstrom, B Shadbolt, M McNiven, A Broomfield, ... Pathology 39 (6), 580-585, 2007 | 38 | 2007 |
| Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL) D Talaulikar, JE Dahlstrom, B Shadbolt, A Broomfield, A McDonald Journal of Histochemistry & Cytochemistry 56 (10), 893-900, 2008 | 34 | 2008 |
| Bisphosphonate guidelines for treatment and prevention of myeloma bone disease OL Lee, N Horvath, C Lee, D Joshua, J Ho, J Szer, H Quach, A Spencer, ... Internal medicine journal 47 (8), 938-951, 2017 | 31 | 2017 |
| Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the … JC Wight, M Yue, C Keane, A Johnston, K Linton, C Chin, SH Wai, ... British journal of haematology 187 (2), 174-184, 2019 | 30 | 2019 |
| DeepSNVMiner: a sequence analysis tool to detect emergent, rare mutations in subsets of cell populations TD Andrews, Y Jeelall, D Talaulikar, CC Goodnow, MA Field PeerJ 4, e2074, 2016 | 30 | 2016 |
